XML 21 R7.htm IDEA: XBRL DOCUMENT v3.22.4
Consolidated Statements of Stockholders' Equity - USD ($)
$ in Thousands
Total
2019 Sales Agreement [Member]
2022 Sales Agreement [Member]
Follow On Public Offering
At The Market Offerings
At The Market Offerings
2019 Sales Agreement [Member]
At The Market Offerings
2022 Sales Agreement [Member]
Regeneron Pharmaceuticals Inc. [Member]
Follow-on Offering [Member]
Follow-on Offering [Member]
Follow On Public Offering
Follow-on Offering [Member]
At The Market Offerings
Follow-on Offering [Member]
At The Market Offerings
2019 Sales Agreement [Member]
Follow-on Offering [Member]
At The Market Offerings
2022 Sales Agreement [Member]
Follow-on Offering [Member]
Regeneron Pharmaceuticals Inc. [Member]
Additional Paid-In Capital
Additional Paid-In Capital
Follow On Public Offering
Additional Paid-In Capital
At The Market Offerings
Additional Paid-In Capital
At The Market Offerings
2019 Sales Agreement [Member]
Additional Paid-In Capital
At The Market Offerings
2022 Sales Agreement [Member]
Additional Paid-In Capital
Regeneron Pharmaceuticals Inc. [Member]
Accumulated Other Comprehensive Income
Retained Earnings
Beginning balance at Dec. 31, 2019 $ 269,881               $ 5           $ 570,493           $ 261 $ (300,878)
Beginning balance, shares at Dec. 31, 2019                 50,198,044                          
Issuance of common stock       $ 296,607 $ 49,461     $ 12,580   $ 2           $ 296,605 $ 49,461     $ 12,580    
Issuance of common stock, shares   2,270,161               11,815,069 2,270,161     925,218                
Exercise of stock options $ 11,574                           11,574              
Exercise of stock options, shares 840,824                                          
Vesting of restricted stock units, shares 82,829                                          
Issuance of shares under employee stock purchase plan $ 1,557                           1,557              
Issuance of shares under employee stock purchase plan, shares 101,911                                          
Equity-based compensation $ 19,903                           19,903              
Other comprehensive income - unrealized gain (loss) on marketable securities (260)                                       (260)  
Net loss (134,231)                                          
Ending balance at Dec. 31, 2020 527,072               $ 7           962,173           1 (435,109)
Ending balance, shares at Dec. 31, 2020                 66,234,056                          
Issuance of common stock       648,315 $ 45,255                     648,315 $ 45,255          
Issuance of common stock, shares   641,709               4,758,620 641,709                      
Exercise of stock options $ 41,094                           41,094              
Exercise of stock options, shares 2,700,886                                          
Vesting of restricted stock units, shares 119,715                                          
Issuance of shares under employee stock purchase plan $ 2,024                           2,024              
Issuance of shares under employee stock purchase plan, shares 30,897                                          
Equity-based compensation $ 47,009                           47,009              
Other comprehensive income - unrealized gain (loss) on marketable securities (2,126)                                       (2,126)  
Other comprehensive loss - equity method investment (507)                                          
Net loss (267,892)                                          
Ending balance at Dec. 31, 2021 $ 1,040,244               $ 7           1,745,870           (2,632) (703,001)
Ending balance, shares at Dec. 31, 2021 74,485,883               74,485,883                          
Issuance of common stock       $ 337,892   $ 38,886 $ 189,011     $ 1   $ 1       $ 337,891   $ 38,885 $ 189,011      
Issuance of common stock, shares     3,395,339     579,788       7,532,751     3,395,339                  
Exercise of stock options $ 14,517                           14,517              
Exercise of stock options, shares 883,954               883,954                          
Vesting of restricted stock units                 $ 147,674                          
Issuance of shares under employee stock purchase plan $ 2,649               77,618           2,649              
Equity-based compensation 91,400                                          
Other comprehensive income - unrealized gain (loss) on marketable securities (1,637)                                       (1,637)  
Other comprehensive loss - equity method investment (3,192)                                       (3,192)  
Net loss (474,186)                                          
Ending balance at Dec. 31, 2022 $ 1,235,584               $ 9           $ 2,420,223           $ (7,461) $ (1,177,187)
Ending balance, shares at Dec. 31, 2022 87,103,007               87,103,007